KRAS and non-small cell lung carcinoma: Among all KRAS mutant NSCLC, the immunotherapy significantly improved PFS (11.7 vs 7.0 months, P < 0.001, Fig. 5A) and OS (23.8 vs 14.7 months, P = 0.013, Fig. 5D) compared to chemotherapy alone; Treatment containing pemetrexed had longer PFS (10.1 vs 6.2 months, P < 0.001, Fig. 5B) and OS (16.4 vs 14.1 months, P = 0.112, Fig. 5E) compared to treatment containing paclitaxel; And patients who received antiangiogenic therapy had significantly longer PFS (10.0 vs 6.5 months, P = 0.031, Fig. 5C) and OS (19.7 vs 13.7 months, P = 0.004, Fig. 5F) than those not.